| Literature DB >> 24861939 |
Seigo Usuki1, Dawn O'Brien1, Michael H Rivner2, Robert K Yu3.
Abstract
The enzyme-linked immunosorbent assay (ELISA) is a standard immunoassay used in measuring antibody reactivity (expressed as titers) for glycosphingolipids (GSLs) such as gangliosides and sulfoglycolipids in the sera of patients with Guillain-Barré syndrome (GBS), variants of GBS, and chronic inflammatory demyelinating polyneuropathy (CIDP). In the present study, anti-GSL antibodies were evaluated using a new formula of affinity parametric complex (APC), calculated from limiting-dilution serum assay data, followed by affinity parametric complex criterion (APCC). Using assay results based on APCC, we analyzed serum samples categorized into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor-sensory axonal neuropathy (AMSAN), CIDP, CIDP with myasthenia gravis (MG), and amyotrophic lateral sclerosis (ALS). We were able to determine the affinity strength of antibodies otherwise hidden in the non-specific background activity in highly adhesive serum samples. The thin-layer chromatography (TLC)-immuno-overlay method assured us that this new method is an accurate and reliable way for evaluating anti-GSL antibodies using ELISA serum sample data. Published by Elsevier B.V.Entities:
Keywords: ALS; Anti-glycolipid antibody; CIDP; ELISA; GBS; Non-specific adhesions
Mesh：
Substances：
Year: 2014 PMID： 24861939 PMCID： PMC4467790 DOI： 10.1016/j.jim.2014.05.005
Source DB: PubMed Journal: J Immunol Methods ISSN： 0022-1759 Impact factor: 2.303